hero section gradient
15 handpicked stocks

Capitalizing on the IPO Boom

A collection of carefully selected stocks that stand to benefit from the surging IPO market. Our professional analysts have identified the financial firms, exchanges, and investment banks that facilitate and profit from this increased capital raising activity.

Author avatar

Han Tan | Market Analyst

Published on July 2

Your Basket's Financial Footprint

Summary and investor takeaways for the provided basket market capitalisation data.

Key Takeaways for Investors
  • Large-cap dominance tends to mean lower volatility, offering more stable, market-tracking performance than small-cap-heavy baskets.
  • Suitable as a core holding for diversification, rather than a concentrated speculative growth position.
  • Likely to deliver steady long-term value; do not expect explosive short-term gains.
Total Market Cap
  • ICE: $89.75B

  • GS: $229.76B

  • NDAQ: $51.83B

  • Other

About This Group of Stocks

1

Our Expert Thinking

With the NYSE raising a record $61 billion in the first half of 2025, companies that facilitate IPOs are seeing substantial revenue growth. This group targets the financial infrastructure behind this capital formation boom, from exchanges earning listing fees to investment banks collecting underwriting fees.

2

What You Need to Know

These stocks have a direct link between IPO volume and their fee-based revenue streams. The nearly 40% increase in capital raising activity signals renewed investor confidence and economic strength, creating a favorable environment for these financial facilitators.

3

Why These Stocks

This collection was handpicked to include the primary beneficiaries of the IPO trend at various market levels. From major exchanges like ICE and NASDAQ to premier underwriters like Goldman Sachs, these companies capture revenue throughout the capital raising process.

Why You'll Want to Watch These Stocks

📈

Record-Breaking Momentum

With NYSE's capital raising up nearly 40% from last year, these companies are riding a powerful wave of increased fee revenue and transaction volume.

💰

Direct Profit Connection

These firms have a straightforward revenue link to IPO activity—more offerings mean more fees, more listings, and more trading, creating a clear path to potential earnings growth.

🔍

Hidden Market Infrastructure

While everyone watches the high-profile IPOs, these companies are quietly collecting fees at every step of the process, regardless of which specific companies go public.

Get the full story on this Basket. Read our detailed article on its risks and potential.

Read Full Insight

Why Invest with Nemo Money?

Nemo Logo Fade
🆓

Zero Commission

Trade stocks, ETFs, and more with zero commission. Keep more of your returns.

🔒

Trusted & Regulated

Part of Exinity Group 2015, serving over a million customers globally.

💰

6% Interest on Cash

Earn 6% AER on uninvested cash with daily interest payments.

Discover More Opportunities

Aerospace Stocks: Could Airbus Issues Boost Boeing?

Aerospace Stocks: Could Airbus Issues Boost Boeing?

Airbus has cut its delivery targets after discovering a significant fuselage flaw in its A320 aircraft, causing production delays and requiring widespread inspections. This situation could create a significant opening for its main competitor, Boeing, and other aerospace manufacturers to capture market share from airlines seeking to avoid delivery uncertainties.

Cargo Capacity Crisis: Which Stocks May Benefit Most?

Cargo Capacity Crisis: Which Stocks May Benefit Most?

The crash of a UPS cargo plane has led to the grounding of an entire class of aging aircraft across the logistics industry. This creates a potential investment opportunity in competing cargo carriers and aircraft manufacturers poised to fill the resulting gap in shipping capacity.

UK-US Pharma Trade Deal | Tariff-Free Market Access

UK-US Pharma Trade Deal | Tariff-Free Market Access

A new trade deal eliminates tariffs on pharmaceuticals between the UK and the US, strengthening transatlantic trade. This creates a powerful tailwind for pharmaceutical companies in both countries, potentially boosting exports, innovation, and profitability.

Frequently Asked Questions